1. Arginase inhibition improves endothelial function in patients with type 2 diabetes mellitus despite intensive glucose‐lowering therapy. (27th August 2018) Authors: Mahdi, A.; Kövamees, O.; Checa, A.; Wheelock, C. E.; von Heijne, M.; Alvarsson, M.; Pernow, J. Journal: Journal of internal medicine Issue: Volume 284:Number 4(2018) Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial. Issue 2 (27th November 2015) Authors: Leiter, L. A.; Teoh, H.; Mosenzon, O.; Cahn, A.; Hirshberg, B.; Stahre, C. A. M.; Hoekstra, J. B. L.; Alvarsson, M.; Im, K.; Scirica, B. M.; Bhatt, D. L.; Raz, I. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 2(2016) Page Start: 186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High plasma lipoprotein(A) levels are associated with increased prevalence of cardiovascular disease and poorer metabolic control in patients with type 1 diabetes mellitus. (December 2020) Authors: Littmann, K.; Wodaje, T.; Alvarsson, M.; Bottai, M.; Eriksson, M.; Parini, P.; Brinck, J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗